(This is a follow up to the earlier blog on Biocon Ltd., where we explored the company’s biologics strategy and India’s gradual shift toward complex therapies. With FY26 developments and recent management commentary now available, this piece revisits that evolving thesis.)
THE CONVERSATION AROUND BIOCON IS CHANGING
For years, the Biocon story was largely about investment.
Building manufacturing capacity. Expanding biosimilars globally. Integrating the Viatris acquisition. Scaling commercial reach across regulated markets.
That phase may finally be nearing completion.
In its FY26 commentary, management repeatedly emphasized something important: the heavy investment cycle is now largely behind the company, and the focus is shifting toward execution, utilisation, margins, cash generation, and return on capital.
That shift matters because the last few years were expensive.
Biocon invested aggressively across biosimilars, insulins, peptides, and complex generics while simultaneously absorbing one of the largest biosimilars transactions in the industry. During this period, debt rose sharply, margins remained under pressure, and investors spent more time debating integration risks than long-term earnings power.
More importantly, the Viatris transaction fundamentally changed Biocon’s role in the biosimilars industry.
Earlier, the company largely participated through partnerships and shared commercialization economics. Today, Biocon controls a much larger part of the value chain across development, manufacturing, and commercialization in regulated markets.
But FY26 may have marked the beginning of a different phase.
Adjusted revenue grew around 13%, while adjusted EBITDA increased nearly 25%, indicating early operating leverage across the business. Biosimilars revenue crossed ₹10,400 crore, growing roughly 16% YoY, while net debt reduced from nearly $1.5 billion to around $1.1 billion.
These comparisons exclude the unusually high Lenalidomide base in the previous year, providing a clearer view of the underlying business trajectory.
Interestingly, the timing of this transition could matter.
Several newer biosimilars are beginning to scale globally just as Biocon’s large investment cycle appears to be peaking. At the same time, interest costs are declining, utilisation levels are improving, and major capacity additions are nearing completion.
For a long time, Biocon was viewed as a company constantly investing ahead of profitability.
The more interesting question now is whether the business is slowly entering a phase where the economics finally begin to catch up with the ambition.
Interestingly, the market still often views Biocon as a company trapped in a long investment cycle. The next few years may determine whether that perception begins to change.
BIOSIMILARS: FROM PIPELINE STORY TO COMMERCIAL SCALE
One of the more interesting shifts inside Biocon today is that the biosimilars business no longer looks dependent on a single product, market, or launch cycle.
Scale is beginning to appear across the portfolio.
In FY26, biosimilars revenue crossed ₹10,400 crore, growing around 16% YoY, while segment EBITDA increased nearly 40% on an adjusted basis. EBITDA margins improved to roughly 26%, reflecting early operating leverage as newer products started scaling commercially.
But the more important shift may be happening underneath those numbers.
Insulin products are now contributing roughly $300 million annually, while the Adalimumab portfolio has crossed $250 million. Products such as Trastuzumab and Pegfilgrastim are each approaching the $200 million mark, and Bevacizumab has already crossed $100 million.
This diversification matters.
Biosimilars businesses often become more stable once revenue starts getting distributed across multiple therapies, treatment areas, and geographies rather than depending heavily on one blockbuster product.
At the same time, newer launches are beginning to gain traction in regulated markets.
Management highlighted strong momentum for Yesintek in the United States, where the product has started contributing meaningfully to the P&L. Ustekinumab biosimilars are also seeing encouraging market share gains, supported by broader insurance coverage and formulary access.
Geographically, too, the business is becoming more balanced. North America remains the primary growth driver, but Europe continues to deliver stable tender-driven execution, while emerging markets are seeing steady expansion through launches and access programs.
And this may be where the Biocon story starts becoming more interesting.
For years, biosimilars at Biocon were largely discussed as future potential. Today, the business is beginning to look increasingly commercial at scale.
THE NEXT GROWTH CYCLE MAY ALSO BE TAKING SHAPE
While most conversations around Biocon still revolve around biosimilars, another part of the business is slowly becoming more interesting.
The generics segment.
At first glance, the numbers may not look extraordinary. FY26 generics revenue grew around 17% YoY on an adjusted basis to nearly ₹3,200 crore, while EBITDA increased roughly 73% YoY on a like-for-like basis.
But the more important story is changing product mix.
Biocon is gradually moving beyond traditional commodity-style generics into more complex therapies such as GLP-1s, peptides, immunosuppressants, and specialty injectables. During FY26, the company secured approvals for gLiraglutide across the US, Europe, and Australia, expanding its exposure to the rapidly growing obesity and diabetes therapy market. It also received approvals for Everolimus in the US and Tacrolimus across Latin America.
More recently, the company also received Health Canada approval for Micafungin for Injection, strengthening its hospital-focused anti-infective portfolio in regulated markets.
Individually, these approvals may appear incremental.
Collectively, they point toward a broader shift.
Many of these therapies sit in categories where manufacturing complexity matters more than scale alone. That matters because the next phase of pharmaceuticals may increasingly reward companies that can manufacture difficult products efficiently rather than simply manufacture cheaply.
Interestingly, management also indicated that major investments across peptides and complex generics are now substantially complete. Which means the next phase may be less about building capacity and more about improving utilisation and monetising the infrastructure created.
And if GLP-1 therapies continue expanding globally, Biocon may be positioning itself much earlier than the market currently realizes.
That opportunity may also be structurally different from traditional generic markets. GLP-1 therapies are increasingly becoming long-duration chronic treatments, where manufacturing reliability, peptide capabilities, and delivery systems could matter as much as pricing.
Interestingly, Biocon’s broader ecosystem also extends beyond biosimilars and generics. Through Syngene, the group continues to maintain exposure to global research and manufacturing outsourcing, supported by long-term partnerships such as Bristol Myers Squibb extending through 2035 and expanding ADC capabilities.
THE ECONOMICS MAY FINALLY BE CATCHING UP WITH THE AMBITION
For a long time, one of the biggest concerns around Biocon was fairly simple.
The company kept investing, but investors struggled to see when the financial returns would begin to show up.
Over the last few years, Biocon invested aggressively across biosimilars, insulins, peptides, complex generics, and manufacturing infrastructure while simultaneously integrating the Viatris biosimilars business. The result was a company carrying elevated debt, pressure on margins, and large capital requirements.
But FY26 commentary suggests the cycle may now be turning.
Management repeatedly emphasized that the major investment phase is largely behind, with the focus shifting toward utilisation, operating leverage, margin expansion, and ROCE improvement.
That transition is beginning to show up in the numbers.
Adjusted EBITDA for FY26 increased around 25%, significantly ahead of revenue growth of roughly 13%, indicating early operating leverage across the business. Biosimilars EBITDA margins improved to nearly 26%, while the generics segment also started seeing sequential margin improvement despite recently commissioned facilities still ramping up.
This becomes particularly important in biologics because manufacturing infrastructure carries very high upfront fixed costs. Once facilities begin operating at higher utilisation levels, incremental revenue can potentially flow through at much stronger margins.
The balance sheet is also beginning to improve.
Net debt has reduced from nearly $1.5 billion to around $1.1 billion, while refinancing and deleveraging are expected to generate annual interest savings of roughly ₹300 crore. At the same time, future capital intensity could moderate meaningfully. Management indicated that no major greenfield capex is currently planned, while major capacity additions across Malaysia and biologics infrastructure are nearing completion.
Perhaps the more interesting detail lies elsewhere.
Biocon indicated that certain biosimilars may no longer require Phase 3 clinical trials, potentially reducing development costs by nearly 50% and accelerating time to market.
In biologics, even small reductions in development time and cost can materially alter long-term economics.
Which raises an important possibility.
After years of building infrastructure, Biocon may finally be entering a phase where the business starts generating operating leverage at scale rather than simply absorbing capital.
IS THE HARD PART ONLY BEGINNING?
Even after the recent improvement, Biocon’s story is still far from straightforward.
Biosimilars remain one of the most competitive segments in global pharmaceuticals. As more companies enter major therapy areas, pricing pressure can intensify quickly, especially in regulated markets such as the US and Europe.
At the same time, biologics manufacturing remains operationally demanding.
Over the last few years, Biocon has received observations at certain manufacturing facilities from global regulators, reminding investors that scaling biologics is very different from scaling traditional generics. Even a single delay in approval, supply disruption, or compliance issue can materially affect commercialization timelines.
The balance sheet, while improving, also continues to reflect the aftereffects of the Viatris acquisition. Net debt has reduced, but leverage still remains elevated relative to many Indian pharmaceutical peers.
And then there is the adoption curve itself.
Unlike traditional generics, biosimilars do not always gain market share immediately after launch. Physician adoption, reimbursement negotiations, insurance coverage, and formulary positioning all influence how quickly products scale commercially.
That becomes especially important because the next few years are likely to depend heavily on execution.
Biocon now has:
- a broader biosimilars portfolio
- global commercial reach
- expanding manufacturing capacity
- and multiple upcoming launches across biosimilars and GLP-1 related therapies
The challenge is no longer about building capabilities. It is about converting those capabilities into sustained profitability, stronger free cash flow, and durable return on capital.
Which is why the next phase of the Biocon story may become more demanding than the build-out phase, which creates an interesting contradiction.
CAN INDIA BUILD A GLOBAL BIOLOGICS CHAMPION?
Biocon today sits at a very different point from where it stood three or four years ago.
Back then, the company was still largely viewed as an ambitious biologics player investing aggressively into a future that remained uncertain. Today, many of those investments are already visible in the business.
Biosimilars portfolio now spans more than 120 countries. Products across insulin, oncology, immunology, and ophthalmology are scaling globally, while newer therapies such as Yesintek, Aspart, and GLP-1 related products could shape the next growth cycle.
At the same time, the financial structure of the business also appears to be changing.
The heavy capex cycle is largely complete. Debt has started reducing. Interest costs are declining. And operating leverage is beginning to emerge as utilisation improves across manufacturing facilities.
That combination can change how biologics businesses behave financially.
The next phase could look very different if recent launches continue scaling and newer products gain traction across regulated markets.
But biologics businesses are rarely linear.
Commercial adoption takes time. Competitive intensity remains high. Regulatory scrutiny never fully disappears. And even strong products can take years to scale meaningfully.
This is why the next few years may be a crucial phase in Biocon’s journey so far.
The company has already spent years proving it can build a global biologics platform. Now it must prove that the platform can generate durable profitability, stronger cash flows, and long-term capital efficiency.
The company has already spent years proving it can build a global biologics platform.
The harder challenge now is proving that such a platform can generate durable profitability, stronger cash flows, and long-term capital efficiency.
In many ways, this may become a larger test for Indian pharmaceuticals itself.
India has already proven it can dominate global generic manufacturing. The next question is whether companies like Biocon can become globally relevant in complex biologics as well.
For years, Biocon’s ambition was visible long before the financial returns were. The next few years may determine whether the economics finally begin catching up with the scale of that ambition.
If you need guidance on how to start your stock market journey, how much capital is enough to begin with, how to do smart investing, or how to take informed stock market decisions, you can join Strategic Alpha’s ‘The Conviction Club’. This is a membership program, especially curated to help investors become aware and knowledgeable about stock market trends, news, and technical aspects, so that they can become their own experts.
Our YouTube channel, weekly webinars, and digital resources available on the website can help you learn the basics of the stock market. For regular updates on trends, one-to-one sessions with experts, and detailed learning modules, you can join the Conviction Club, which is the online community of like-minded investors sharing knowledge and thoughts to grow together.
Subscribe to the Strategic Alpha Newsletter now to get the latest updates about weekly webinars.
Join Me On My Telegram Channel Where I Share Much More Value Adding Knowledge Of Investing/ Trading: Click Here
Also, Don’t Forget To Follow Us On Our Social Media Accounts:
Facebook: https://www.facebook.com/strategicalpha/
Instagram: https://www.instagram.com/strategicalpha/
Twitter: https://twitter.com/suyog_dhavan
YouTube: https://bit.ly/2IIqztO
Disclaimer: Strategic Alpha and Suyog Dhavan are not SEBI-registered investment advisor. The content provided is purely for educational purposes and should not be construed as financial or investment advice. Viewers are encouraged to conduct their own research or consult with a SEBI-registered professional before making any investment decisions.
